About olaparib
PARP inhibitor anticancer medicine
Used for
- Treats certain ovarian, fallopian tube, and peritoneal cancers
- Treats certain breast, pancreatic, and prostate cancers
Usual adult dose
Usually 300 mg by mouth twice daily; the dose may be adjusted for kidney function, side effects, or interactions.
Common side effects
- Nausea, vomiting, diarrhoea, or reduced appetite
- Tiredness, headache, or dizziness
- Anaemia, low white blood cells, or low platelets
- Increased risk of infection or bruising
Important warnings
- Can rarely cause serious bone marrow disorders or leukaemia
- Blood tests are needed during treatment
- Seek urgent assessment for fever, unusual bruising, or severe weakness
- Some medicines can greatly change olaparib levels
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for six months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for one month after the last dose.
Interactions
- Avoid strong or moderate CYP3A inhibitors, including some antifungals and antibiotics
- Avoid strong or moderate CYP3A inducers, including rifampicin and some seizure medicines
- Olaparib can interact with hormonal contraceptives and other medicines; review all medicines
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.